CR20220014A - Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos - Google Patents

Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Info

Publication number
CR20220014A
CR20220014A CR20220014A CR20220014A CR20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A CR 20220014 A CR20220014 A CR 20220014A
Authority
CR
Costa Rica
Prior art keywords
pyridazin
diamino
derivatives
pharmaceutical compositions
compositions containing
Prior art date
Application number
CR20220014A
Other languages
English (en)
Inventor
Simon Bedford
Miklós Nyerges
András Kotschy
Jérôme-Benoît Starck
András Herner
Monika Rudasová
Marianna Szigeti
Paul Webb
Márk Molnár
Mátyás Pál Timári
Tibor Novák
Petra Dunkel
Ágnes Strofek
James Edward Paul Davidson
James Brooke Murray
Maïa Chanrion
Patrice Desos
Attila Paczal
Frédéric Colland
Mark Philip Dodsworth
Ana Leticia Maragno
Zoltán Madarász
Rachel Jane Parsons
Original Assignee
Vernalis R&D Ltd
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd, Servier Lab filed Critical Vernalis R&D Ltd
Publication of CR20220014A publication Critical patent/CR20220014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de fórmula (I) en donde Het1, Het2, R1, R2 y R3 son como se definen en la descripción. Medicamentos.
CR20220014A 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos CR20220014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19188747 2019-07-29
PCT/EP2020/071179 WO2021018857A1 (en) 2019-07-29 2020-07-28 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

Publications (1)

Publication Number Publication Date
CR20220014A true CR20220014A (es) 2022-03-02

Family

ID=67514281

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220014A CR20220014A (es) 2019-07-29 2020-07-28 Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos

Country Status (24)

Country Link
US (1) US20220289734A1 (es)
EP (1) EP4003988A1 (es)
JP (1) JP7646626B2 (es)
KR (1) KR20220042182A (es)
CN (1) CN114450283B (es)
AR (1) AR119493A1 (es)
AU (1) AU2020322072A1 (es)
BR (1) BR112022001330A2 (es)
CA (1) CA3148502A1 (es)
CL (1) CL2021003594A1 (es)
CO (1) CO2022000700A2 (es)
CR (1) CR20220014A (es)
DO (1) DOP2022000015A (es)
GE (2) GEAP202415866A (es)
IL (1) IL289932B2 (es)
JO (1) JOP20220006A1 (es)
MX (1) MX2022001161A (es)
PE (1) PE20220704A1 (es)
PH (1) PH12022550018A1 (es)
PY (1) PY2039849A (es)
SA (1) SA522431498B1 (es)
TW (1) TWI900486B (es)
UY (1) UY38809A (es)
WO (1) WO2021018857A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021386367A1 (en) * 2020-11-24 2023-06-22 Les Laboratoires Servier Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN117794929A (zh) * 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
IL317102A (en) 2022-05-20 2025-01-01 Novartis Ag EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
CN120787162A (zh) 2022-05-20 2025-10-14 诺华股份有限公司 抗肿瘤化合物的抗体-药物缀合物及其使用方法
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗ｃｄ７抗體藥物結合物及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005561A (es) 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
BRPI0821209A2 (pt) * 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK3305785T3 (da) * 2015-05-29 2021-10-11 Teijin Pharma Ltd Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf

Also Published As

Publication number Publication date
KR20220042182A (ko) 2022-04-04
IL289932A (en) 2022-03-01
BR112022001330A2 (pt) 2022-05-17
CO2022000700A2 (es) 2022-02-07
CN114450283A (zh) 2022-05-06
TWI900486B (zh) 2025-10-11
AU2020322072A1 (en) 2022-02-10
PH12022550018A1 (en) 2022-10-17
CL2021003594A1 (es) 2022-11-18
UY38809A (es) 2021-02-26
JP2022542937A (ja) 2022-10-07
US20220289734A1 (en) 2022-09-15
JP7646626B2 (ja) 2025-03-17
PY2039849A (es) 2021-05-06
DOP2022000015A (es) 2022-05-15
GEP20247670B (en) 2024-09-25
SA522431498B1 (ar) 2025-04-13
WO2021018857A1 (en) 2021-02-04
IL289932B2 (en) 2026-02-01
PE20220704A1 (es) 2022-05-04
JOP20220006A1 (ar) 2023-01-30
EP4003988A1 (en) 2022-06-01
CA3148502A1 (en) 2021-02-04
TW202118761A (zh) 2021-05-16
CN114450283B (zh) 2024-05-07
IL289932B1 (en) 2025-10-01
NZ784583A (en) 2025-02-28
AR119493A1 (es) 2021-12-22
MX2022001161A (es) 2022-02-22
GEAP202415866A (en) 2024-06-10

Similar Documents

Publication Publication Date Title
CO2022000612A2 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
CO2022000700A2 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CL2019003281A1 (es) Derivados de piperidina. (divisional solicitud 201900169)
ES2039269T3 (es) Derivados de azolilmetil-ciclopropilo.
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018001908A1 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen.
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY30493A1 (es) Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
PY2201650A (es) Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
CL2020001817A1 (es) Moduladores del receptor c5a
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
PY1953761A (es) Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas que los contienen
PY2027937A (es) Hidroxiisoxazolinas y derivados de las mismas
PY2027940A (es) Hidroxiisoxazolinas y derivados de las mismas